................................ 69 6.4 Primary and secondary efficacy endpoints ................................ ................ 71 6.5 Exploratory efficacy endpoints ................................ ................................ .73 6.6 Safety and tolerability endpoints ................................ ............................... 74 6.7 Interim analysis ................................ ................................